Clinical trialPhase 3Completed
Clinical Trial Testing TH-302 in Combination With Gemcitabine in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma
A Randomized, Double-Blind, Phase III Study of the Efficacy and Safety of Gemcitabine in Combination With TH-302 Compared With Gemcitabine in Combination With Placebo in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma
- Outcome
- Outcome unknown
- Phase
- Phase 3
- Status
- Completed
- Study type
- Interventional
- Start
- December 2012
- Expected end
- May 2016
- Enrollment
- 693 participants
- Sites
- 2
- Primary outcomes
- Overall Survival
- Sponsor
- Industry
- Results posted
- 2017-12-02
- Last update
- 11 May 2025
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
This Phase 3 trial is a randomized, double-blind, placebo-controlled trial of gemcitabine in combination with TH-302 compared to gemcitabine in combination with placebo in subjects with locally advanced unresectable or metastatic pancreatic adenocarcinoma. Randomized subjects will receive TH-302 plus gemcitabine or gemcitabine plus placebo in 4-week cycles until there is evidence of progressive disease, intolerable toxicity, or the subject discontinues from the trial for other reasons (for example, withdrawal of consent). The primary efficacy endpoint is overall survival (OS) time. The data cut-off for statistical analyses of the primary and secondary endpoints will be reached when 508 events (deaths) will be reported. No planned interim analyses will be conducted. An Independent Safety Monitoring Board (ISMB) will provide periodic evaluations of the unblinded safety data to ensure subject safety and the validity and scientific merit of the study. A total of 660 subjects will be enrolled.
Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)
Overall Survival [From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years]. Median, months (95% Confidence Interval). Gemcitabine Plus TH-302 (n=346): 8.9 (7.6 to 9.9); Gemcitabine Plus Placebo (n=347): 7.6 (6.7 to 8.3).
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Progression Free Survival [From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years]. Median, months (95% Confidence Interval). Gemcitabine Plus TH-302 (n=346): 5.5 (4.8 to 5.6); Gemcitabine Plus Placebo (n=347): 3.7 (3.6 to 3.8).